RxDoctor Payments Data

Kunal Kanitkar, MD

Ophthalmology · Lexington, SCNPI 1639210925

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $66,540 of the $83,322 with a category attached, or 79.9%. Sun Pharmaceutical Industries Inc. accounts for 90.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $24,041 and has fallen 56.5% since, to $10,468 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$83,322in general payments, 2019–2025

Across 434 payments — averaging $191.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$76K
  • AbbVie$897
  • Alcon$771
  • Sight Sciences, Inc.$655
  • Biotissue Holdings Inc.$541
  • Aerie Pharmaceuticals, Inc.$483
  • plus $4K from 25 others

What the payments were for

  • Speaking & faculty fees$66,54080%
  • Travel & lodging$5,5227%
  • Food & beverage$11,16713%
  • Education$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,322 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$666,559
Medicare patients
1,680
Services billed
5,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine159$144,046
LumiganBimatoprost218$107,640
XiidraLifitegrast100$84,684
Cyclosporine161$69,164
TyrvayaVarenicline Tartrate36$30,132
CequaCyclosporine46$29,456
RhopressaNetarsudil Mesylate43$21,638
RocklatanNetarsudil Mesylat/Latanoprost44$19,642
VyzultaLatanoprostene Bunod30$13,022
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol64$12,187
CombiganBrimonidine Tartrate/Timolol29$10,468
MieboPerfluorohexyloctane/Pf14$10,429
Loteprednol Etabonate66$8,772
Prednisolone Acetate221$8,638
Travoprost29$8,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$897$262,155406 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$369$108,135144 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$483$41,27987 claims
Oyster Point Pharma, Inc.Tyrvaya$185$30,13236 claims
Sun Pharmaceutical Industries Inc.Cequa$75,756$29,45646 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Alrex$475$16,821100 claims
AlconSimbrinza$771$6,60021 claims
Eyevance Pharmaceuticals LLCTobradex St$16$3,25414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →